Nobel-Prize Winner Peter C. Doherty, Ph.D., and Philadelphia-Area Business Leader Vincent G. Bell, Jr., Named Emeritus Wistar Institute Board Members

Nobel-Prize Winner Peter C. Doherty, Ph.D., and Philadelphia-Area Business Leader Vincent G. Bell, Jr., Named Emeritus Wistar Institute Board Members

December 7, 2006

(PHILADELPHIA - December 8, 2006) – The Wistar Institute’s Board of Trustees has named Nobel-Prize winner Peter C. Doherty, Ph.D., and Vincent G. Bell, Jr., a Philadelphia-area business leader, as emeritus members of the Board. Resolutions in their honor were passed by unanimous vote of the full Board at its December 8 meeting. Both men were recognized for their years of service to The Wistar Institute, an international leader in biomedical research.

“Wistar has benefited tremendously from the steady guidance and wisdom of these talented and dedicated individuals,” said Russel E. Kaufman, M.D., president and CEO of The Wistar Institute. “Dr. Doherty’s scientific expertise and counsel ensured that Wistar’s research programs consistently aimed for answers to the most important questions in biomedicine. Mr. Bell’s business acumen ensured that the Institute shepherded its resources appropriately and planned well for the future, so that it could effectively pursue its ambitious research goals.”

“Dr. Doherty and Mr. Bell have contributed greatly to the extraordinary progress we see being made by The Wistar Institute today,” said Brian H. Dovey, chairman of Wistar’s Board of Trustees. “Wistar is a world-class research organization today, thanks in good part to the efforts of these two men.”

Dr. Doherty was an investigator at Wistar from 1975 to 1982. He is currently Laureate Professor at the Department of Microbiology and Immunology in the University of Melbourne, Australia, and the Michael F. Tamer Chair of Biomedical Research at St. Jude Children’s Research Hospital. He joined Wistar’s Board of Trustees in 1997. In 1996, Dr. Doherty and colleague Rolf M. Zinkernagel M.D., Ph.D., shared the Nobel Prize in Physiology or Medicine for research that laid the foundation for understanding how immune system cells recognize both foreign and self molecules. The work led to major breakthroughs in treating viral infections and cancers and in developing organ-transplant procedures and vaccines. Dr. Doherty joined Wistar as an associate professor in 1975 and was later promoted to professor. He returned to the Australian National University John Curtin School of Medical Research in 1982 as department chair, became chairman of immunology at St. Jude Children’s Research Hospital in 1988, and currently holds professorial appointments at both St. Jude and the University of Melbourne School of Medicine.

Mr. Bell began his business career as co-founder of a home building business in 1954. In 1956, he co-founded Safeguard Business Systems Inc., a firm that provides manual and computerized products and services to more than one million small businesses and professionals in the United States, Canada, and the United Kingdom. Its products include accounting systems, automated payroll services, business forms, and filing systems. Prior to its sale to a Texas merchant in 1986, Safeguard’s annual operating revenues exceeded $300 million. In 1987, Mr. Bell founded Versus Corporation, a private investment company that invests and participates in the management of a number of small businesses.

Mr. Bell joined the Wistar Board in 1995. He has also served on the boards of or as an advisor to Hunt Manufacturing Company, Envirite Corporation, Safeguard Scientifics Inc., Safeguard Business Systems Inc., BHC Securities Inc., and Devon Manor.

In addition, Mr. Bell was chairman of Paoli Memorial Hospital, vice chairman of Main Line Health Inc., vice chairman of the Hospital Trustee Association of Pennsylvania, vice president and chairman of the World Affairs Council of Philadelphia, and director of the Chief Executives Organization Inc.

The Wistar Institute is an international leader in biomedical research, with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. Discoveries at Wistar have led to the creation of the rubella vaccine that eradicated the disease in the U.S., rabies vaccines used worldwide, and a new rotavirus vaccine approved in 2006. Wistar scientists have also identified many cancer genes and developed monoclonal antibodies and other important research tools. Today, Wistar is home to eminent melanoma researchers and pioneering scientists working on experimental vaccines against flu, HIV, and other diseases. The Institute works actively to transfer its inventions to the commercial sector to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today’s Discoveries – Tomorrow’s Cures. On the web at